Adaptive resistance to anti-PD-1 therapy also correlated with VISTA upregulation in melanoma patients, suggesting that VISTA blockade, possibly combined with PD-1 blockade, represents a potentially efficacious treatment strategy45. Here, PDCD1 is linked to melanoma.